Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
‘Risk children’s lives for some extra manpower’: IRGC recruits 12 year olds to fill personnel gaps - 2Experience Sports in Dubai: A Daredevil's Aide
- 3Most loved Solace Food: What's Your Definitive Comfortable Dinner?
- 4Elite Execution Wall televisions for Film Darlings
- 5Gulf aluminum output tumbles on Iran war
- Smuggler who called migrants 'chickens' jailed
- Transcript: Scott Gottlieb on "Face the Nation with Margaret Brennan," Dec. 7, 2025
- The Developing Nearby Food Development and Its Advantages
- From Lounge chair to Money: Online Positions That Will Change Your Profession
- Shelby County deputies charged with assault, placed on leave
- Hamas propaganda expert explains Israel's internal conflicts influenced Hamas's Oct. 7 assault
- Modern surgery began with saws and iron hands – how amputation transformed the body in the Renaissance
- Cameroon says Russia has confirmed 16 Cameroonian soldiers died in Ukraine
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
